ARTRYA®
Coronary Artery Disease.
We see you.

QUARTERLY ACTIVITIES & CASHFLOW REPORT
QUARTER ENDED 30 JUNE 2026

Investor Conference Call at 10.00am AEST (8.00am AWST) on 30 July 2026

PERTH, Australia, 29 July 2026: Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix® AI-powered cloud platform, for the real time, point of care assessment and management of coronary artery disease globally, is pleased to release its Appendix 4C – Quarterly Cashflow Report and Activities Update for the quarter ended 30 June 2026 (the **Quarter**). All financial results are in Australian dollars and are unaudited.

Highlights

- **U.S. foundation customers continue to progress commercially - Tanner Health using Salix® routinely in clinical practice - Northeast Georgia Health System went live in July 2026 as a second revenue-generating customer**
  - Cone Health progressing toward deployment
- **Artrya continues to build scalable implementation capabilities, with real-time reimbursement workflow initiatives supporting scale and faster customer adoption**
- **Salix® Coronary Flow validation progressed towards completion, with FDA submission imminent and clearance and commercial launch targeted for second half of CY26**
- **SAPPHIRE Study commenced with investigator meeting held at the SCCT Annual Scientific Meeting and site activities progressing**
- **Commercial pipeline expanding with SAPPHIRE health systems progressing toward commercial discussions**
- **Clinical Advisory Board formation advanced, strengthening Artrya's U.S. clinical strategy**
- **Pro forma cash position of $74.0M at 30 June 2026**

John Konstantopoulos, Co-Founder and CEO of Artrya commented:

"This Quarter marked another major step forward for Artrya, as our U.S. commercial and clinical strategies continued to move into execution. Salix® continues to gain traction across our U.S. foundation customers, with Tanner Health now using the platform in routine clinical practice, Northeast Georgia Health System going live in July, and Cone Health progressing toward deployment.

During the Quarter, we continued to build the operational foundations required to scale adoption, including real-time reimbursement workflow initiatives that will support scale and growth in our plaque and flow modules as we continue to implement across U.S. health systems. We also achieved important clinical and regulatory milestones, finalising the Salix® Coronary Flow validation program and progressing our FDA submission following receipt of the required U.S. clinical datasets.

The commencement of the SAPPHIRE Study and establishment of our Clinical Advisory Board further strengthen our clinical strategy and provide an important pathway to accelerate adoption of Salix® across leading U.S. health systems.

With a strong balance sheet, expanding commercial pipeline and increasingly repeatable deployment model, Artrya is well positioned to accelerate the commercialisation of Salix®."

Commercial rollout gathers pace across three U.S. foundation customers

Artrya continued to build its U.S. commercial foundation across its three initial health system customers during the Quarter. Tanner Health remains Artrya's most advanced customer, with Salix® Coronary Anatomy and Salix® Coronary Plaque fully live and in routine clinical use across all five hospitals, supporting growth in scan volumes and fee-per-scan revenue.

The Company continued working closely with Tanner Health to streamline reimbursement workflows and accelerate pre authorisations, which both support Salix® adoption and scale. These initiatives are expected to form part of Artrya's broader implementation strategy, supporting efficient deployment, utilisation, and accelerated reimbursement as additional U.S. health systems adopt Salix®.

At Northeast Georgia Health System (**NGHS**), deployment of Salix® Coronary Anatomy commenced during the Quarter and was completed in July 2026, making NGHS Artrya's second revenue-generating customer. The Company will continue expanding Salix® across the broader NGHS hospital network to drive adoption and utilisation.

At Cone Health, Artrya's Customer Success team continues to work closely with cardiology and IT teams to complete integration activities ahead of clinical deployment.

Across all three customers, the focus for the coming Quarter will be increasing scan volumes at Tanner Health, expanding utilisation across the NGHS network and progressing Cone Health toward full clinical deployment. Artrya's objective is for all three foundation customers to be generating Salix® Coronary Anatomy and Plaque revenues by the end of the September Quarter.

Artrya continues to build commercial traction as SAPPHIRE partners progress toward commercialisation

Artrya continued to expand its U.S. commercial pipeline during the Quarter, with increasing commercial engagement from leading health systems evaluating the Salix® platform.

The Company is leveraging the SAPPHIRE Study as both a clinical evidence program and a commercialisation strategy, as the participating health systems are gaining experience with Salix® while generating evidence to support broader adoption, in the commercial pilot phase.

During the Quarter, Artrya continued to advance commercial discussions with a number of SAPPHIRE sites, with leading U.S. health systems evaluating the role of Salix® in improving workflow efficiency and enhancing CCTA and coronary artery disease assessment pathways. This engagement is building a pipeline of future commercial opportunities and supports Artrya's strategy to expand adoption across the U.S. healthcare market.

Salix® Coronary Flow module validated and FDA submission imminent

Artrya completed validation and pre-submission activities for its Salix® Coronary Flow module during the Quarter, progressing the Company's 510(k) application to the U.S. Food and Drug Administration (**FDA**). A key milestone during the Quarter was securing the required clinical datasets from participating U.S. sites, enabling completion of the validation program and finalisation of submission activities.

Salix® Coronary Flow provides near real-time, non-invasive assessment of coronary blood flow from standard CT scans, generating Fractional Flow Reserve (**FFR**) measurements to help clinicians identify patients who may safely avoid unnecessary invasive angiography.

Upon FDA clearance, Coronary Flow will complete Artrya's integrated platform, combining coronary anatomy assessment, plaque characterisation and physiological blood flow assessment within a single CCTA examination. Salix® Coronary Flow assessments will be eligible for reimbursement under an existing Category I CPT code, currently reimbursed at US$877 per scan.

The Company continues to target FDA clearance and commercial launch in the second half of calendar 2026.

SAPPHIRE Study commenced as Investigators hold first meeting in San Diego, U.S.

Artrya officially kicked off the SAPPHIRE Study, with investigators from a number of participating U.S. health systems gathering in San Diego on 9 July 2026 during the Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography (**SCCT**).

The protocol reviews, contracting and ethics activities are now progressing with all SAPPHIRE sites, with initial retrospective data collection for the Study expected to commence upon completion of these activities. The SAPPHIRE Study will evaluate the ability of Salix® Coronary Plaque and Artrya's proprietary Plaque Dispersion Score to improve coronary artery disease identification, risk stratification and management.

Importantly, SAPPHIRE is also a key component of Artrya's commercialisation strategy, embedding Salix® within leading U.S. health systems while creating opportunities to transition research collaborations into long-term commercial relationships.

Artrya strengthens clinical leadership with formation of Clinical Advisory Board advancing

During the Quarter, Artrya advanced the formation of its Clinical Advisory Board (**CAB**), securing commitments from leading U.S. cardiovascular imaging specialists. The Board will provide strategic guidance across clinical practice, product development, evidence generation and adoption of the Salix® platform.

The CAB will be chaired by Dr Ron Blankstein of Mass General Brigham, Professor of Medicine at Harvard Medical School and Principal Investigator of the SAPPHIRE Study. The participation of leading cardiovascular specialists strengthens Artrya's clinical engagement and supports the continued evolution of Salix® in alignment with clinician and health system needs.

FINANCIAL & CORPORATE MATTERS

Investor engagement

This Quarter, Artrya continued its growing investor engagement programme, attending the 2026 Morgan Stanley Australian Summit in Sydney during June and completing several non-deal roadshows in Australia and in Hong Kong. The efforts to build deeper relationships with brokers and investment banks is ongoing, with Barrenjoey initiating research coverage in addition to research coverage already provided by Petra Capital, Bell Potter, and Venn Brown.

Operating Cashflows for the Quarter & Cash position

During the Quarter, the Company's cashflows from operating activities included:

- **Customer receipts** of $0.06M related to receipt of subscription and per scan revenues from Tanner Health;
- **Operating costs** (excluding interest income and R&D rebate) of $6.4M, down from $6.8M in the prior quarter, primarily due to a reduction in R&D costs. Operating costs included technical work to finalise and validate Salix® Coronary Flow module and prepare the FDA submission, alongside operational costs supporting the U.S. customer rollout;
- **R&D rebate** of $0.5M relating to a previous financial year. This is supplementary to the $5.6M R&D rebate received in the March 2026 quarter;
- **Interest income** of $1.2M;
- **Related party payments** of $0.2M for fees and salaries paid to Directors and their related entities.

Additionally, there were Financing cash inflows for the Quarter of $2.3M, related to the exercise of options.

In line with the Company's prudent deployment of resources, the total Net Cash Outflows for the Quarter were $2.6M.

The Company holds a $30.0M six month, bank term deposit as part of treasury management activities. This term deposit is classified as a financial asset under AASB 9 and is not considered cash or cash equivalents for the purposes of the Appendix 4C. The investment is readily realisable but does not meet the definition of cash equivalents due to its maturity exceeding three months.

The Company held $74.0M of cash and term deposits at 30 June 2026.

Quarterly Investor Webinar

The Company's Co-Founder and CEO John Konstantopoulos, will host a Quarterly Investor Webinar at **10.00am AEST (8.00am AWST)** on **30 July 2026**, to discuss the Company's activities and results and the business outlook. A recording of the webinar will be available on the Investor Centre section of the Company's website for 60 days after the call. Shareholders will also have an opportunity to participate in a Q&A session at the end of the briefing.

Date: **30 July 2026**

Time: **10.00am AEST / 8.00am AWST**

To pre-register for this conference, please use the following link below:

https://artrya.zoom.us/webinar/register/WN_f2Lc_hvER3uq6UFuGVaGYw

- Ends -

This ASX Announcement is authorised for release by the Board of Artrya Limited.

About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to Identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through Innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit **www.artrya.com** or follow us on LinkedIn at **www.linkedin.com/company/artrya**

For more information:

Corporate Enquiries

John Konstantopoulos
Co-Founder and Chief Executive Officer
Tel: +61 8 6478 7816
Email: contact@artrya.com

Investor & Media Enquiries

David Allen or John Granger
Hawkesbury Partners
Tel: +61 499 100 038 or +61 410 577 155
Email: investors@artrya.com

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target", "outlook", "guidance" and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Artrya. The Estimates and Projections are based on information available to Artrya as at the date of the Announcement, are based upon management's current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to Artrya's business and the industry in which it operates

which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of Artrya and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by Artrya in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. Artrya takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Artrya Limited	
ABN	**Quarter ended ("current quarter")**
53 624 005 741	30 June 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (12 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	60	176
1.2	Payments for		
	research and development	(1,082)	(3,676)
	product manufacturing and operating costs	(1,599)	(6,254)
	advertising and marketing	(160)	(652)
	leased assets	(91)	(372)
	staff costs	(2,848)	(10,177)
	administration and corporate costs	(671)	(2,773)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	1,169	2,184
1.5	Interest and other costs of finance paid	(3)	(17)
1.6	Income taxes paid	4	(1)
1.7	Government grants and tax incentives	471	6,037
1.8	Other (provide details if material)	-	(835)
1.9	**Net cash from / (used in) operating activities**	**(4,750)**	**(16,360)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(70)	(156)
	(d) investments (term deposit)	-	(30,000)
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
2.2	Proceeds from disposal of:		
	(g) entities	-	-
	(h) businesses	-	-
	(i) property, plant and equipment	-	-
	(j) investments	-	-
	(k) intellectual property	-	-
	(l) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(70)**	**(30,156)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	80,000
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	2,265	4,110
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(4,871)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other	-	-
3.10	**Net cash from / (used in) financing activities**	**2,265**	**79,239**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	46,584	11,332
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(4,750)	(16,360)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(70)	(30,156)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	2,265	79,239
4.5	Effect of movement in exchange rates on cash held	(4)	(30)
4.6	**Cash and cash equivalents at end of period**	**44,025**	**44,025**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	44,025	46,584
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**44,025**	**46,584**

**** The Company has invested $30 million of its cash reserves into a short-term, six month bank deposit as part of treasury management activities. This term deposit is classified as a financial asset under AASB 9 and is not considered cash or cash equivalents for the purposes of this Appendix 4C. Accordingly, the investment is excluded from cash and cash equivalents at quarter end. The investment is readily realisable but does not meet the definition of cash equivalents due to its original maturity exceeding three months.***

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	240
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (see table 7.6 below)	-	-
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

n/a

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(4,750)
8.2	Cash and cash equivalents at quarter end (item 4.6)	44,025
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	44,025
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)** **Note: The Company has available investment funds held in a short term, six month bank term deposit of $30 million that is excluded from cash and cash equivalents at the quarter end. The investment is readily realisable but does not meet the definition of cash equivalents due to its original maturity exceeding three months.**	9.27

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?
Answer: N/A	

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: **29 July 2026**

Authorised by: **Board of Directors, Artrya Limited**

(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – e.g. Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.